paclitaxel + carboplatin + trastuzumab + pertuzumab

This regimen is a **combination therapy** consisting of two chemotherapy agents (**paclitaxel**, a taxane-class microtubule inhibitor; and **carboplatin**, a platinum-based DNA crosslinker) with two targeted monoclonal antibodies (**trastuzumab** and **pertuzumab**, both anti-HER2 agents). This combination is used as neoadjuvant or metastatic therapy in HER2-positive cancers (predominantly breast, and more recently endometrial). Trastuzumab binds to the HER2 receptor (subdomain IV), blocking signaling and promoting immune-mediated cytotoxicity (ADCC, ADCP, CDC). Pertuzumab binds a different HER2 domain (subdomain II), preventing dimerization with HER3 and further inhibiting proliferation. Paclitaxel disrupts mitosis by stabilizing microtubules, and carboplatin induces DNA damage via platinum crosslinks. Together, the regimen offers synergistic cytotoxic and targeted effects, leading to high response and pathologic complete response rates, particularly in HER2-positive breast cancer[7][6][3][1][10]. Main indications: HER2-positive breast cancer (neoadjuvant, adjuvant, metastatic), HER2-positive endometrial cancer[1][7][10]. Developers of components: Paclitaxel (Bristol Myers Squibb), Carboplatin (various, originally Bristol Myers Squibb), Trastuzumab (Genentech/Roche), Pertuzumab (Genentech/Roche).

Brand names

Herceptin (trastuzumab)Perjeta (pertuzumab)

Other names

TCHP